Harvard Bioscience (HBIO) Capital Expenditures (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Capital Expenditures data on file, last reported at $426000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 16.96% year-over-year to $426000.0 in Q1 2026; TTM through Mar 2026 was $1.2 million, a 53.38% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, down 52.42% from the prior year.
• Capital Expenditures for Q1 2026 stood at $426000.0, down from $449000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for HBIO reached as high as $880000.0 in Q3 2024 and fell as low as $89000.0 in Q2 2025.
• Historically, Capital Expenditures has averaged $453294.1 across 5 years, with a median of $442000.0 in 2022.
• Across the five-year window, Capital Expenditures soared 305.53% in 2024 and slumped 89.12% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $235000.0 in 2022, then surged by 253.19% to $830000.0 in 2023, then sank by 63.73% to $301000.0 in 2024, then soared by 49.17% to $449000.0 in 2025, then slipped by 5.12% to $426000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $426000.0 in Q1 2026, $449000.0 in Q4 2025, and $207000.0 in Q3 2025.